期刊文献+

结核分枝杆菌融合蛋白Ag85B-Hsp16.3、Ag85B-ESAT6和分泌蛋白Hsp16.3体外对人肝癌细胞HepG-2的作用

Effect of Ag85B-Hsp16.3 Ag85B-ESAT6 and Hsp16.3 of Mycobacterium Tuberculosis on Human Hepatoma Carcinoma Cell HepG-2 in Vitro
原文传递
导出
摘要 目的:探讨结核分枝杆菌融合蛋白Ag85B-Hsp16.3、Ag85B-ESAT6及分泌蛋白Hsp16.3对人肝癌细胞HepG-2的作用。方法:将已构建的含3种目的基因的表达载体pProEXHTa-Ag85B-Hsp16.3、pProEXHTa-Ag85B-ESAT6和pProEXHTb-Hsp16.3,分别转入宿主菌E.coliDH5α中,诱导表达后分别获得Ag85B-Hsp16.3、Ag85B-ESAT6和Hsp16.3三种蛋白,采用Ni2+亲和层析柱进行纯化,并用透析方法进行目的蛋白的复性。复性的蛋白按照不同浓度和作用时间分别与肝癌细胞HepG-2反应,用MTT法检测细胞生长情况。结果:三种蛋白被成功纯化并复性。MTT数据统计分析显示,终浓度10μg/ml的三种蛋白对HepG-2细胞生长没有明显作用,当三种蛋白的终浓度分别为20、40、80μg/ml时均能够抑制HepG-2细胞的生长,并且抑制作用随着蛋白终浓度的增大以及作用时间的延长而增强。不同类别的蛋白抑制作用没有明显差别。结论:结核分枝杆菌的部分分泌蛋白能够抑制肝癌细胞HepG-2的生长。 To investigate the effect of Ag85B-Hsp16.3, Ag85B-ESAT6 and Hspl6.3 of Mycobacterium tuberculosis (MTB) on HepG-2 in vitro. Methods:The three recombinant plasmids (pProEXHTa-Ag85B-Hsp 16.3, pProEXHTa-Ag85B-ESAT6 and pProEXHTb-Hspl6.3) were transfered into E.coli DH5a respectively. The three proteins were induced by IPTG and purified by Ni-NTA purification system under denaturing condition. Following renaturation by dialysis and filtration, the three proteins were respectively added into HepG-2 cells of various concent ration (101xg/ml,201xg/ml,401μg/ml and 801μg/ml). The cells were incubated for 24h or 48h, and then the inhibition rate was examined by MTT test assay. Results:The proteins were successfully purified and all had a moderate killing effect on Hepg-2 cells. The effect was dependent on the concent ration of the protein as well as the action time.But there was no statistical difference between different proteins. Conclusion: Some of the secreted proteins of Mycobacterium tuberculosis can inhibit cell growth of liver caricer cell HepG-2.
出处 《现代生物医学进展》 CAS 2011年第10期1801-1804,共4页 Progress in Modern Biomedicine
基金 国家"863"专项课题(2007AA02Z473) 国家自然科学基金(NO.30972767) 陕西省自然科学基金项目(SJ08C203)资助
关键词 结核分枝杆菌 AG85B ESAT6 HSP16.3 肝癌 HEPG-2 Mycobacterium tuberculosis Ag85B ESAT6 Hspl6.3 HepG-2
  • 相关文献

参考文献22

  • 1Harth G, Lee BY, Wang J, et al. Novel insights into the genetics, biochemistry and immunocytochemistry of the 30-kilodalton major extracellular protein of Mycobacterium tuberculosis[J].Infect Immtm, 1999,64(8):3038-3047.
  • 2Simons MP, Nauseef WM, Griffith TS. Neutrophils and TRAIL: insight into BCG immunotherapy for bladder cancer [J]. Immuno Res, 2007,39(1-3):79-93.
  • 3Zlotta AR, van Vooren JP, Huygen K, et al. What is the optimal regimen for BCG intravesical therapy Are six weekly instillations necessary [J]. Eur Uro, 2000,37(4):470-477.
  • 4刘浒,唐四元.骨形成蛋白-2通过JNK信号通路促进肝癌HepG2细胞凋亡[J].实用预防医学,2009,16(4):1021-1024. 被引量:2
  • 5Pogiela T, Kulig J, Czupryna A, et al. Efficiency of adjuvant immunochemotherapy following curative resection in patients with locally advanced gastric cancer[J], Gastric Cancer, 2004,7(4):240-245.
  • 6张廷芬,师长宏,朱德生,张海,赵勇,白冰.结核分枝杆菌Hsp16.3的表达、纯化和鉴定[J].中国人兽共患病学报,2007,23(10):964-967. 被引量:10
  • 7Starck J, Kallenius G, Marklund BI, et al.Comparative protcome analysis of Mycobacterium tuberculosis grown under aerobic and anaerobic conditions[J].Microbiology,2004,150(11):3821-3829.
  • 8Amling CL. Diagnosis and management of superficial bladder cancer [J], Curr Prob Cancer, 2001,25(4):219-278.
  • 9Kaasinen ES, Harju LM, Alfthan OS, et al. Non-specific, rapidly generated cytotoxicity in lymphocytes induced by BCG in vitro: no evidence of enhancing effect from preceding interaction between BCG and transitional cell line cells[J]. J Uro, 2000,163(1):317-322.
  • 10Morales A, Eidingcr D, Bruce AW. Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors[J]. J Uro, 1976,116 (2):180-183.

二级参考文献35

  • 1Juan Zhang~1 Jin-Kun Zhang~2 Shao-Hong Zhuo~3 Hai-Bin Chen~2 1 Clinical Laboratory,The First Affiliated Hospital of Shantou University Medical College,Shantou 515041,Guangdong Province,China2 Cancer Pathology Laboratory,Shantou University Medical College,Shantou 515031,Guangdong Province,China3 Department of Gastroenterology,Third Municipal Hospital of Shantou,Shantou 515073,Guangdong Province,China.Effect of a cancer vaccine prepared by fusions of hepatocarcinoma cells with dendritic cells[J].World Journal of Gastroenterology,2001,7(5):690-694. 被引量:26
  • 2Bao-GangPeng Li-JiangLiang QiangHe MingKuang Jia-MingLia Ming-DeLu Jie-FuHuang.Tumor vaccine against recurrence of hepatocellular carcinoma[J].World Journal of Gastroenterology,2005,11(5):700-704. 被引量:28
  • 3周丽蓉,罗永艾.结核病血清学诊断的新进展[J].中国实用内科杂志,2005,25(3):269-271. 被引量:21
  • 4李秀青,王琦.肝癌中骨形成蛋白2对PTEN蛋白水平影响的研究[J].中国药物与临床,2007,7(1):24-26. 被引量:7
  • 5Harth G, Lee BY, Wang J,et al. Novel insights into the genetics, biochemistry, and immunocytochemistry of the 30-kilodalton major extracellular protein of Mycobacterium tuberculosis[J]. In fect Immun, 1999,64(8) : 3038-3047.
  • 6Lim JH, Park JK,Jo EK, et al. Purification and immunoreactivity of three components from the 30/32-kilodahon antigen 85 complex in Mycobacterium tuberculosis [J]. Infect Immun, 1999,67 (11) :6187-6190.
  • 7Kariyone A, Tamura T, Kano H, et al. Immunogenicity of Pep tide-25 of Ag85B in Thl development: role of IFN gamma [J]. Int Immunol, 2003,15 (10) : 1183-1194.
  • 8Doherty TM, Demissie A, Olobo J, et al. Immune responses to the Mycobacterium tuberculosis-specific antigen ESAT-6 signal subclinical infection among contacts of tuberculosis patient [ J]. Clin Microbiol, 2002,40 : 704- 706.
  • 9Britton WJ,Palendira U. Improving vaccines against tuberculosis [J]. Immunology and cell biology, 2003,81(1):34- 35.
  • 10Morris S,Kelley C,Howard A,et al. The immunogenicity of single and combination DNA vaccines against tuberculosis [J]. Vac cine,2000,18(20) :2155- 2163.

共引文献38

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部